Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 0.86 |
| ▸ | TXK | P42681 | 1/20 | 0.86 |
| ▸ | BMX | P51813 | 1/20 | 0.86 |
| ▸ | ITK | Q08881 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207228 | 1.00 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL1531602 | 0.92 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL10207414 | 0.92 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL10207964 | 0.91 | BTK (0.83) | BTKTECTXKBMXITK | |
| SCHEMBL1531539 | 0.90 | BTK (0.82) | BTKTECTXKBMXITK | |
| SCHEMBL10207715 | 0.90 | BTK (0.82) | BTKTECTXKBMXITK | |
| SCHEMBL1531569 | 0.90 | BTK (0.82) | BTKTECTXKBMXITK | |
| SCHEMBL10207231 | 0.90 | BTK (0.82) | BTKTECTXKBMXITK | |
| SCHEMBL10206518 | 0.90 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL1532234 | 0.90 | BTK (0.82) | BTKTECTXKBMXITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | TELIOS PHARMA INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250064805-A1 | Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate | TELIOS PHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20240293403-A1 | Treatment of Symptoms Associated with Myeloproliferative Neoplasms | TELIOS PHARMA, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | TELIOS PHARMA, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| CN-114423457-A | Method for treating splenomegaly | 泰利奥斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2485589-A1 | HETEROARYL BTK INHIBITORS | Biogen Idec MA Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | BTK 1/4885TEC 7/4885TXK 339/4885 |
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, KIT, LYN | BTK 1/4885TEC 304/4885TXK 458/4885 |
| US-20240293403-A1 | Treatment of Symptoms Associated with Myeloproliferative Neoplasms | ABL1, BTK, JAK2 | BTK 2/4885TEC 239/4885TXK 381/4885 |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | BTK, LYN, ABL1 | BTK 1/4885TEC 324/4885TXK 785/4885 |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | BTK, SYK, LCK | BTK 1/4885TEC 40/4885TXK 290/4885 |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, LYN, ABL1 | BTK 1/4885TEC 324/4885TXK 785/4885 |
| US-20250064805-A1 | Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate | BTK, ABL1, MPL | BTK 1/4885TEC 138/4885TXK 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.